Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNC105P plus everolimus versus everolimus in clear cell renal cell carcinoma
ACTRN12613000063718Phase 2Active, not recruiting
- Sponsor
- Neuphoria Therapeutics Inc.
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of BNC105P and everolimus in clear cell renal cell carcinoma (ccRCC), sponsored by Neuphoria Therapeutics Inc. Primary endpoint: 6-month progression-free survival. Started Sep 2011; status: active, not recruiting.
02
Drugs
BNC105Peverolimus
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ACTRN12613000063718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000063718.